Mawer Investment Management Ltd. Makes New Investment in Repligen Corporation $RGEN

Mawer Investment Management Ltd. bought a new position in Repligen Corporation (NASDAQ:RGEN – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 29,300 shares of the biotechnology company’s stock, valued at approximately $5,632,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Bank of Nova Scotia purchased a new position in shares of Repligen during the second quarter worth approximately $3,547,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Repligen in the 2nd quarter valued at $1,173,000. American Capital Management Inc. bought a new position in shares of Repligen during the 2nd quarter valued at $49,262,000. Corient Private Wealth LP grew its holdings in shares of Repligen by 420.9% during the 2nd quarter. Corient Private Wealth LP now owns 11,319 shares of the biotechnology company’s stock valued at $1,544,000 after purchasing an additional 9,146 shares during the last quarter. Finally, Tidal Investments LLC grew its holdings in shares of Repligen by 75.2% during the 2nd quarter. Tidal Investments LLC now owns 8,863 shares of the biotechnology company’s stock valued at $1,209,000 after purchasing an additional 3,803 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of recent research reports. UBS Group reaffirmed a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Barclays raised their price target on Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Canaccord Genuity Group boosted their price objective on Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Weiss Ratings lowered Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research note on Monday, November 2nd. Finally, JPMorgan Chase & Co. lifted their target price on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $178.57.

Read Our Latest Stock Analysis on Repligen

Repligen Price Performance

Shares of RGEN stock opened at $167.79 on Monday. The stock has a market cap of $10.73 billion, a P/E ratio of -798.96, a PEG ratio of 2.88 and a beta of 1.11. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $198.87. The company has a quick ratio of 8.43, a current ratio of 9.88 and a debt-to-equity ratio of 0.27. The company’s fifty day simple moving average is $177.15 and its two-hundred day simple moving average is $145.67.

Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The firm had revenue of $209.31 million during the quarter, compared to analyst estimates of $206.70 million. During the same quarter last year, the business posted $0.46 earnings per share. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. Analysts predict that Repligen Corporation will post 2.07 EPS for the current fiscal year.

About Repligen

(Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

See Also

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.